Reply to the letter to the editor "Long-term cannabinoid receptor (CB1) blockade in obesity: implications for the development of colorectal cancer".
Santoro
Antonietta
A
Gazzerro
Patrizia
P
Malfitano
Anna Maria
AM
Pisanti
Simona
S
Laezza
Chiara
C
Bifulco
Maurizio
M
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000494:pharmacology*; D019440:Anti-Obesity Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D002277:Carcinoma / Q000139:chemically induced / Q000517:prevention & control*; D002470:Cell Survival / Q000187:drug effects; D015179:Colorectal Neoplasms / Q000139:chemically induced / Q000517:prevention & control*; D004305:Dose-Response Relationship, Drug; D006801:Humans; D051379:Mice; D009765:Obesity / Q000188:drug therapy*; D010880:Piperidines / Q000494:pharmacology; D011720:Pyrazoles / Q000494:pharmacology; D043884:Receptor, Cannabinoid, CB1 / Q000037:antagonists & inhibitors*; D000077285:Rimonabant; D013997:Time Factors
D000893:Anti-Inflammatory Agents; D019440:Anti-Obesity Agents; D000970:Antineoplastic Agents; D010880:Piperidines; D011720:Pyrazoles; D043884:Receptor, Cannabinoid, CB1; C103505:AM 251; D000077285:Rimonabant